As a practitioner and researcher, I like to share important information on new treatments and clinical trials that may become available to patients and the health care community.
A number of research and clinical trials have been completed and undergone in regards to LDN immunotherapies, with phase I and phase II clinical trials successfully run at a number of universities in the United States and Europe. *
LOW-DOSE NALTREXONE (LDN)
Naltrexone is an opioid antagonist used primarily in the management of alcohol and opioid dependence; the FDA approved Naltrexone in 1984 at 50mg. However, there is “Accumulating evidence that suggests LDN can promote health supporting immunemodulation, which reduces various oncogenic inflammatory autoimmune processes.”
There are a number of conditions where LDN could benefit based on clinical studies and patient data.
Click here for the complete LDN Fact Sheet or visit http://www.lowdosenaltrexone.org/ * to see additional information, resources and testimonials.
To schedule an appointment with Dr. Dagstani, or for additional information, please call us directly at 480.861.3916. We look forward to working with you and restoring you to optimum health.
Healthy Isn’t A Goal, It’s A Way Of Living!
